drugset / Trial / NCT02392910

Hospitalization & Mortality in Patients With Iron Deficiency CKD and HF Treated With i.v. Iron.

NCT02392910

Phase 4 Completed 40 enrolled Hospital Aleman
RandomizedParallel-groupDouble-blindTreatment

Summary

Iron deficiency, independent of anemia, appears to increase morbidity and mortality as well as impairing health-related quality of life in chronic heart failure (CHF), and these effects are compounded when patients also experience chronic kidney disease (CKD). This study was designed to determine the effects of intravenous iron treatment on morbidity and mortality following an initial 6-month period and a longer period of up to 5 years.

Timeline

Start
2006-03
Primary completion
2012-02
Completion
2012-02

Drugs

EvaluationDrugModalityDoseRoute
Subject Iron sucrose Unknown 200 mg Intravenous